


**2024
Institutional
Investors'
Conference**




Adimmune Corporation

Accelerate Vaccines into the Future



Disclaimer


- Adimmune has not released any financial forecast. Business and financial information presented in this brief and during the Q&A session, should they concern business operation or industrial development, may differ materially from actual results. These discrepancies are due to such risks and uncertainties as market demand changes, price fluctuations, competitive behavior, global economic conditions, exchange rate fluctuations, supply chains etc., which are beyond Adimmune's control.
- The forward-looking statements contained in this brief are based on Adimmune's current expectations and speak only as of the date hereof. Adimmune assumes no obligation to update forward-looking statements as the result of new information or future events or developments.



Agenda Overview

- **Company Profile**
- **Financial Highlights for the Q3 of FY2024**
- **Business Outlook**
- **Q&A**





The only influenza vaccine manufacturer in Asia with both EMA & US FDA GMP certifications


Established **since 1965 (60-year experience in vaccines)**
Chairman **Chi-Shean Chan, M.D.**
Employees **525 (as of Nov. 2024)**
Total Area **38,831 square meters**
Products **Influenza Vaccine, Enterovirus 71 Vaccine, Tetanus Vaccine, Tuberculin**

Technology
Partner



Partners





Agenda Overview

- Company Profile
- Financial Highlights for the Q3 of FY2024
- Business Outlook
- Q&A



FY2024 Q3

Consolidated Income Statement

Unit : NT\$ Thousands


Items	2024.Q3		2023.Q3	
	Reviewed	%	Reviewed	%
Sales Revenues	888,242		973,345	
Operating Costs	(447,969)		(488,399)	
Net operating margin	440,273	50%	484,946	50%
Operating expenses	(171,562)		(285,873)	
Selling expenses	(47,792)		(7,585)	
General and administrative expenses	(73,598)		(86,913)	
Research and development expenses	(50,176)		(83,707)	
Expected credit impairment gains(losses)	4		(107,668)	
Operating profit	268,711		199,073	
Non-operating income and expenses	(25,434)		30,219	
Profit before income tax	243,277	27%	229,292	24%
Income tax expense	-		-	
Net Profit	243,277		229,292	
Consolidated Net Income Attributed to Parent Company	263,296		263,707	
Consolidated Net Income Attributed to Subsidiaries	(20,019)		(34,415)	
EPS	0.62		0.63	

FY2024 Q1-Q3

Consolidated Income Statement

Unit : NT\$ Thousands


Items	2024.Q1-Q3		2023.Q1-Q3	
	Reviewed	%	Reviewed	%
Sales Revenues	1,011,920		1,225,604	
Operating Costs	(676,959)		(895,927)	
Net operating margin	334,961	33%	329,677	27%
Operating expenses	(553,604)		(668,624)	
Selling expenses	(140,920)		(70,159)	
General and administrative expenses	(224,393)		(241,510)	
Research and development expenses	(188,448)		(229,602)	
Expected credit impairment gains(losses)	157		(127,353)	
Operating profit	(218,643)		(338,947)	
Non-operating income and expenses	(47,284)		30,335	
Profit before income tax	(265,927)	(26%)	(308,612)	(25%)
Income tax expense	-		-	
Net Profit	(265,927)		(308,612)	
Consolidated Net Income Attributed to Parent Company	(194,457)		(226,015)	
Consolidated Net Income Attributed to Subsidiaries	(71,470)		(82,597)	
EPS	(0.46)		(0.54)	



Agenda Overview

- Company Profile
- Financial Highlights for the Q3 of FY2024
- Business Outlook
- Q&A






Business Outlook

Adimmune's own products & CDMO

	2023	2024				2025				2026			
	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
QIV for South Hemisphere	Submission of marketing authorization & documentation review					On-site inspection (scheduled) & audit in Taiwan				Acquisition of marketing authorization & commercial production			
EV71 Vaccine-ASEAN									Submission of marketing authorization/documentation review/on-site inspection				
CDMO: Production Scaling (A Company)			Clarification of business terms & technical specifications		On-site inspection & audit in Taiwan			Acquisition of marketing authorization		Scaling commercial production			
CDMO: Filling Service for Intravitreal Injection	On-site inspections for the North America/Europe/Northeast Asia markets & acquisition of marketing authorization					Annual commercial production for filling service							

* Enterovirus 71 vaccine is expected to obtained the marketing authorizations in ASEAN countries in 2027-2029.





Business Outlook

Strategic Development & New Product R&D Collaboration

- **Ongoing overseas expansion of quadrivalent influenza vaccine**
 - **Southern hemisphere market (Brazil)**
 - **Middle East and South Asia**
- **Strategic partners for new product co-development and technology transfer**
 - **Zoster vaccine (Korea)**
 - **Microneedle patch for influenza vaccine**
 - **Dual vaccine against Respiratory Syncytial Virus (RSV) and Influenza (Asia & Southern hemisphere)**





Business Growth: Phase II

Phase I Globalization Expansion Strategy

Phase II Acceleration

Phase II Growth


Unit : NT\$ 0.1 Billion


Obtained the market authorization for influenza vaccine in China

Adimmune began its globalization strategy in 2015 with the acquisition of marketing authorization for its influenza vaccine in China. Since then, the company has achieved significant growth in both Adimmune's products and CDMO services, expanding its footprint from Taiwan to major global markets, including the U.S., Europe, China, Northeast Asia, Southeast Asia, Central Asia, and Eastern Europe.

By 2023, Adimmune successfully completed Phase I of its global expansion strategy. The strong performance of its partners in international markets has further solidified and strengthened these strategic partnerships.


As Adimmune moves into Phase II of its business growth, the company is building on the successful foundation established during Phase I of its global expansion and aims to drive further growth in its CDMO business, expand its own product portfolio into the southern hemisphere market, and introduce its bioreactor-derived Enterovirus 71 vaccine to the ASEAN region.





Q & A





THANK YOU

OFFICE



No. 3, Sec. 1, Tanxing Rd.,
Tanzi Dist., Taichung City
427003 , Taiwan (R.O.C.)



+886-4-25381220



[https://www.adimmune.com.
tw/en](https://www.adimmune.com.tw/en)

TWSE: 4142

